US6468989B1 - Gel compositions containing metronidazole - Google Patents
Gel compositions containing metronidazole Download PDFInfo
- Publication number
- US6468989B1 US6468989B1 US09/615,169 US61516900A US6468989B1 US 6468989 B1 US6468989 B1 US 6468989B1 US 61516900 A US61516900 A US 61516900A US 6468989 B1 US6468989 B1 US 6468989B1
- Authority
- US
- United States
- Prior art keywords
- metronidazole
- concentration
- hpcd
- niacinamide
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Definitions
- the invention pertains to the field of topically applied medications for treatment of skin and mucosal disorders.
- the invention pertains to aqueous gel compositions containing metronidazole as the active ingredient.
- Metronidazole 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
- metronidazole has also been shown to be useful in treating various skin disorders, including acne rosacea, bacterial ulcers, and perioral dermatitis.
- Metronidazole has been found to have an anti-inflammatory activity when used topically to treat dermatologic disorders. See, Czernielewski, et al., U.S. Pat. No. 5,849,776.
- Metronidazole may also be used as an intravaginal therapeutic agent for the treatment of bacterial vaginosis. See, Borgman, U.S. Pat. No. 5,536,743.
- compositions containing metronidazole for treatment of dermatologic disorders are available in both cream and gel forms.
- One commercially available metronidazole cream product, NORITATETM (Dermik Laboratories, Inc., Collegeville, Pa. 19426 USA) contains 1% metronidazole and is directed to be applied once daily to affected areas.
- a commercially available metronidazole gel product, METROGEL® (Galderma Laboratories, Inc. Fort Worth, Tex., 76133 USA), contains 0.75% and is applied twice daily to affected areas.
- Creams typically oil in water emulsions
- ointments typically petroleum jelly based compositions
- oil-based cream and ointment metronidazole formulations have an advantage over gel-based formulations in that oil-based formulations may contain a concentration of metronidazole of 1%.
- Aqueous-based gel compositions are limited to a concentration of metronidazole of 0.75% because of the poor solubility of metronidazole in water. Because of this, metronidazole gel products must be applied on at least a twice daily basis.
- Cyclodextrins especially ⁇ -cyclodextrins, have been shown to enhance the solubility of various drugs in aqueous solutions. Yie W. Chien, Journal of Parenteral Science and Technology, 38(1):32-36 (January 1984), describes the increase in water solubility of MTZ by addition of niacinamide. The Chien article is incorporated herein by reference.
- the cyclodextrins and niacinamide enhance solubility by formation of a “cage” structure having an external hydrophilic face and an internal hydrophobic face.
- Stella PCT application International Publication WO 91/11172, discloses that digoxin is five times more water soluble when combined with BCD than when it is combined with HPCD. Stella also discloses that testosterone and phenytoin are more water soluble when combined with BCD than when combined with HPCD.
- EP 0335545 B1 discloses that a 50% w/w concentration of HPCD increases the water solubility of several drugs, including chlordiazepoxide, dexamethasone, diazepam, estradiol, ethynylestradiol, medazepam, methotrexate, norethindrone, norethindrone acetate, norgestrel, oxazepam, phenytoin, and all-trans-retinol.
- Bodor further discloses that, in order to obtain a particular dissolved concentration of an estradiol compound, the concentration of HPCD must be maintained above 20% because, at levels less than this, the solutions are unstable and precipitation occurs.
- Muller WO 85/02767 discloses that certain hydroxyalkylated derivatives of BCD, including hydroxyethyl, hydroxypropyl, and dihydroxypropyl BCD, increase the solubility of various drugs in aqueous solution.
- Muller discloses that 10% HPCD increases the solubility of indomethacin, digitoxin, progesterone, dexamethasone, hydrocortisone, and diazepam in a phosphate buffer aqueous solution. No information was provided concerning the stability of these solutions.
- Muller further discloses that solutions of 4% hydroxypropyl-methyl-BCD increased the solubility of several compounds, including several imidazole compounds, and that solutions of 7% hydroxyethyl-BCD increased the solubility of indomethacin.
- the drugs dissolved in these solutions were found to be chemically stable, as determined by high pressure liquid chromatography. Muller does not address the problem of physical stability over time as described in Bodor regarding solutions containing less than 50% HPCD.
- aqueous solutions of higher than 0.75% metronidazole (MTZ) w/w may be obtained by combining in the solution an amount of hydroxypropyl-betacyclodextrin (HPCD), preferably at a level less than 20%.
- HPCD hydroxypropyl-betacyclodextrin
- HPCD hydroxypropyl-betacyclodextrin
- niacinamide has a synergistic effect in increasing the solubility of MTZ in water.
- the invention is an aqueous solution having a concentration of MTZ higher than 0.75% w/w.
- the aqueous solution contains HPCD, or a combination of HPCD and niacinamide.
- the level of HPCD is less than 20% and the concentration of niacinamide is less than that which, without HPCD, increases the concentration of MTZ to the level of that in the aqueous solution.
- the solution is substantially free of MTZ solubility-enhancing agents other than HPCD or other than HPCD in combination with niacinamide.
- the solution is an aqueous gel.
- the invention is a method for the manufacture of an aqueous solution of MTZ having a concentration greater than 0.75%.
- the method includes combining MTZ and HPCD, or MTZ, HPCD, and niacinamide, in a water based solution wherein the concentration of the final aqueous solution of MTZ is higher than 0.75%.
- the level of HPCD is less than 20%
- the concentration of niacinamide is less than that which, by itself, increases the concentration of MTZ to the level of that in the aqueous solution.
- a gelling agent is further combined with the MTZ and HPCD or with the MTZ, HPCD, and niacinamide.
- the invention is a method for the treatment of a dermatologic or mucosal disorder.
- the method includes topically applying to affected areas an aqueous solution of MTZ and HPCD, or of MTZ, HPCD, and niacinamide, in which the concentration of MTZ is higher than 0.75%.
- the concentration of HPCD is less than 20%
- the concentration of niacinamide is less than that which, by itself, increases the concentration of MTZ to the level of that in the aqueous solution.
- the aqueous solution is a gel.
- the invention is a kit for the treatment of a dermatologic or mucosal disorder.
- the kit of the invention includes a container that contains an aqueous solution of MTZ and HPCD or of MTZ and HPCD and niacinamide, in which the concentration of MTZ is higher than 0.75%, and instructions for topically applying the aqueous solution once daily to affected areas.
- the concentration of HPCD is less than 20%
- the concentration of niacinamide is less than that which, by itself, increases the aqueous solubility of MTZ to the level of MTZ in the aqueous solution.
- FIG. 1 is a graph showing the concentration of MTZ in aqueous solution as a function of the concentration of HPCD.
- FIG. 2 shows a diagrammatic representation of a preferred embodiment of the kit of the invention.
- aqueous solutions of metronidazole (MTZ) of greater than 0.75% w/w are able to be obtained by including hydroxypropyl-betacyclodextrin (HPCD), preferably at a level of less than 20% w/w in the solution, or by including HPCD and niacinamide in the solution, wherein HPCD is preferably less than 20% w/w of the solution and niacinamide is at a level less than the level at which it by itself raises the solubility of MTZ to the level in the solution.
- HPCD hydroxypropyl-betacyclodextrin
- the term “stable” refers to physical, rather than chemical, stability.
- the present invention overcomes the problems noted in the prior art of precipitation of solutes at levels of HPCD of less than 20%. See Bodor, EP 0335545B1, incorporated herein by reference, at page 52.
- the metronidazole solutions of the invention are physically stable, that is substantially no precipitation of metronidazole from solution, when stored at refrigerated temperatures of 5° C. for 14 days or longer.
- the physically stable aqueous solutions of metronidazole at concentrations greater than 0.75% are obtained without the substantial presence of water-miscible organic solvents, such as propylene glycol, which may be irritating to intact or damaged skin or mucosal surfaces.
- organic solvents such as propylene glycol
- the elimination of these organic solvents provides a therapeutic solution that has decreased potential for irritation and makes the solutions especially good for treating topical dermatologic conditions, such as acne rosacea, that may be worsened by irritating chemicals present in a therapeutic formulation.
- such organic solvents may be included in the solution, up to a concentration of about 10%.
- the aqueous solutions are substantially free of solvents for MTZ other than water.
- the stable aqueous MTZ solutions of the invention have a concentration of MTZ greater than 0.75% w/w.
- the concentration of MTZ in the solution of the invention is about 1.0%.
- the concentration of MTZ in aqueous solution may be even higher, such as 1.25%, 1.5%, 2.0%, or 2.5%, or more.
- the aqueous solution may be effectively used therapeutically as a topical formulation on a once daily regimen.
- Presently available topical MTZ therapeutic aqueous solutions must be applied at least twice daily.
- the solution is preferably in the form of a gel. Therefore, the aqueous MTZ solution preferably contains a gelling agent.
- a gelling agent Any gelling agent that is water-dispersible and forms an aqueous gel of substantially uniform consistency is suitable for use in the solution of the invention so long as the gelling agent does not substantially interfere with the water solubility of MTZ or with the therapeutic efficacy of the solution. “Substantially interfere” means that the inclusion of the gelling agent decreases the solubility of MTZ to 0.75% w/w or less in aqueous solution or that it necessitates the administration of the topical solution to be more than once per day.
- a preferred gelling agent is hydroxycellulose (NATROSOLTM, Hercules Inc., Wilmington, Del., USA).
- the level of HPCD in the solution may be varied depending upon the desired dissolved concentration of MTZ. In general, it is preferable to use as low a concentration of HPCD as possible to obtain the desired concentration of MTZ because the presence of HPCD may be irritating to certain intact and diseased skin and mucosal surfaces.
- the concentration of HPCD in aqueous solution may be between 0.5% and 20%, or higher.
- the concentration of HPCD in the solution is no more than about 4% or 5% w/w. Most preferably, the concentration of HPCD is between 1% and 2%.
- the solutions, especially in gel formulation, have been found to be non-tacky, fast-drying, and cosmetically elegant.
- the solutions, including the gel formulations, are physically stable at 5° C. refrigerator or room temperature conditions. No crystal formation or precipitation is observed after one month or more of storage.
- the aqueous solution of the invention be substantially free of compounds other than MTZ having a water-solubility which is increased by the presence of HPCD. These other compounds may act as competitors for the sequestration sites within the HPCD cage structure and reduce the MTZ solubility enhancement of the HPCD. Multiple solutes that are increased in solubility by HPCD may be utilized in the solutions so long as the level of HPCD in the solution is sufficiently high to result in the desired dissolved concentration of MTZ, even in the presence of the competitor solute.
- the amount of HPCD is reduced to a level below that which enhances the solubilization of MTZ to the level desired, and niacinamide is included in the solution at a level that permits the desired concentration of MTZ in aqueous solution to be attained.
- niacinamide is included in the solution at a level that permits the desired concentration of MTZ in aqueous solution to be attained.
- HPCD a stable 1% MTZ aqueous solution
- the amount of niacinamide to be combined in the solution is less than that which, without the presence of HPCD in the solution, can enhance the solubility of MTZ sufficiently to obtain a 1% solution of MTZ, or whatever level of MTZ is desired.
- the amount of HPCD % w/w in the solution is preferably at least equal to that of niacinamide. Most preferably, the concentration of HPCD in the solution is at least 1.5 times that of niacinamide.
- aqueous solutions including the aqueous gels, of the invention may be made in any way that results in a stable MTZ concentration of greater than 0.75%, preferably of 1.0% or higher.
- the solubility enhancer HPCD, or HPCD and niacinamide, and the MTZ are combined in water, or a water-based solution, before the addition of a gelling agent, or at least before gelling of the solution occurs.
- the HPCD, or HPCD plus niacinamide are dissolved in water before addition of the MTZ.
- an aqueous solution of HPCD is prepared having the desired concentration of HPCD.
- an HPCD and niacinamide aqueous solution is prepared, wherein the levels of HPCD and niacinamide are as described above.
- Metronidazole is then added to the solution.
- the amount of metronidazole added to the solution may be an amount calculated to provide the desired concentration of MTZ or it may be an excess amount of MTZ.
- the solution is preferably stirred or agitated at an elevated temperature and then permitted to cool to room or refrigerator temperature.
- a gelling agent if desired, is preferably added at any time after the addition of MTZ to the solution. Most preferably, the gelling agent is added to the solution after the agitation of the solution, during the cooling of the solution, or following cooling of the solution.
- the solutions of the invention may be used for the topical treatment of dermatologic or mucosal disorders that are responsive to therapy with metronidazole.
- a stable aqueous solution containing metronidazole at a concentration higher than 0.75% w/w, preferably about 1% or higher is topically applied to skin or mucosal surfaces in need of such therapy.
- the applied solution preferably contains HPCD, as described above, or a combination of HPCD and niacinamide, as described above.
- the therapeutic method of the invention may be used to treat any disorder that is responsive, or potentially responsive, to metronidazole therapy.
- disorders that are suitably treated in accordance with the invention include inflammatory lesions on the skin, oral mucosa, or vaginal mucosa, diabetic foot ulcers, and certain infectious diseases that may be treated topically.
- the method of the invention is used to treat acne rosacea.
- the application of the metronidazole solution is preferably only once daily.
- the solution is applied on a daily basis, one or more times per day, for a time sufficient to produce an amelioration or a cure of the disorder.
- the solution may be applied once or more times daily for a prolonged period to prevent worsening of the disorder.
- a kit for the topical treatment of skin or mucosal disorders.
- the kit contains a jar 201 or other container suitable for holding an aqueous metronidazole solution as described herein, and instructions (not illustrated) for applying the solution topically to affected areas of the skin or mucosal surface.
- the metronidazole solution has a concentration of metronidazole of about 1% or higher and the instructions call for applying the metronidazole solution to affected areas once daily.
- the jar 201 is preferably packaged within a box 202 , upon which additional information, such as instructions, may be written.
- HPCD hydroxypropyl-beta-cyclodextrin
- stable aqueous metronidazole at the following concentrations may be obtained with the following concentrations of HPCD as shown in Table 1 and FIG. 1 .
- a stable 1.0% aqueous gel was prepared in accordance with Example 1 with the following components:
- a stable 1.25% aqueous gel was prepared in accordance with Example 1 with the following components:
- a stable 1.0% aqueous gel was prepared in accordance with the following components:
- metronidazole solutions were prepared with various derivatives of cyclodextrin at varying concentrations. The solutions were stored at room temperature and were observed for the presence of precipitation, which would indicate that the solutions were not physically stable. Solutions of MTZ and HPCD were found to be stable, whereas solutions of identical metronidazole concentration made with other derivatives of cyclodextrin were found to be unstable. The solutions that were stable at room temperature were then subjected to refrigerator temperature, 5° C., a more rigorous test of physical stability, to determine their physical stability at this lower temperature. The data is shown in Table 3.
- 1% metronidazole solutions containing 5% HPCD were more physically stable than those containing the same amount of gamma-cyclodextrin or maximally dissolvable concentrations of beta-cyclodextrin.
- MTZ solutions with alpha-cyclodextrin were also stable at room temperature and for five days of refrigeration.
- 1.5% concentration of MTZ 10% solutions of the cyclodextrin derivatives other than HPCD were unstable at room temperature, with precipitation of MTZ occurring at one day at room temperature.
- the 1.5% MTZ solution containing 10% HPCD was determined to be stable at room temperature and at refrigeration for at least 10 days.
- Table 4 shows the composition of four samples of metronidazole solutions.
- the release pattern of metronidazole was evaluated for each of the four samples described in Table 4. The release pattern was also evaluated for a commercial 1% metronidazole cream, NORITATETM and for a commercial 0.75% metronidazole gel, METROGELTM.
- the release study was conducted with Franz Diffusion Cells using SpectraporTM membrane (available from Spectrum Medical Industries, Inc., Los Angeles, Calif. 90054) having a molecular weight cutoff of between 12,000 and 14,000.
- the membrane had been soaked for one hour in a buffer having a pH of 5.5.
- the temperature of the Franz Diffusion Cell system was maintained at 32° C.
- the volume of the sample was replaced each time with fresh solution.
- the samples were analyzed for metronidazole by flow injection analysis monitored at 319 nm.
- Release rate data expressed as mg/cm 2 per unit time was identical for Sample A and the commercial metronidazole cream, each of which contains 1% metronidazole.
- Sample B which was identical to Sample A except that Sample B contains no glycerin, had a slightly lower release rate than Sample A and the commercial cream. However, the difference appeared to be insignificant.
- the release pattern of 0.75% metronidazole formulations were nearly identical to that of the 1.0% formulations up to 60 minutes. After that time, the 0.75% formulations had a decreased release rate compared to the 1.0% formulations, most likely due to more rapid depletion of metronidazole from the less concentrated formulations.
- Example 1 Six sample solutions were prepared as described in Example 1 except as follows. Two groups of three sample solutions each were prepared. In one group of three samples, the solubility enhancer was 4% hydroxypropyl-betacyclodextrin (HPCD). In the other group of three samples, the solubility enhancer was 4% hydroxyethyl-betacyclodextrin (HECD). Into the three samples in each group an excess amount of one of the imidazole compounds metronidazole, ketoconazole, or itraconazole, respectively, was added. The solubility of each of the samples was determined as shown in Table 5 and was compared to the solubility of the imidazole in purified water without a solubility enhancer.
- HPCD hydroxypropyl-betacyclodextrin
- HECD hydroxyethyl-betacyclodextrin
- the solubility of metronidazole was increased with the addition of 4% HPCD to purified water by about 20% and with 4% HECD by about 30%.
- the solubility of ketoconazole was increased about 100 and 300 per cent, respectively.
- the increase in solubility was not measurable for either HPCD or HECD.
- the 4% HECD and metronidazole solution became yellow upon addition of the metronidazole, suggesting that this solution was unstable.
- the 4% HPCD and metronidazole solution remained clear and colorless.
- the data in Table 5 shows that the increase in solubility of a drug due to its interaction with a particular derivative of betacyclodextrin cannot be predicted based upon the increase in solubility obtained with a different, even a closely related, derivative of betacyclodextrin.
- the data in Table 5 further shows that the increase in solubility of a drug due to its interaction with a derivative of betacyclodextrin cannot be predicted based upon the increase in solubility of a different drug, even a closely related drug, with that betacyclodextrin derivative.
- HPCD and niacinamide solutions were prepared and the concentrations of each to obtain a stable 1% metronidazole solution at 5° C. were determined as 5% and 3%, respectively. Then various combinations of HPCD and niacinamide concentrations in aqueous solution containing 1% metronidazole were prepared as in Example 1.
- HPCD concentration was in the range of 0% to 5% and the concentration range of niacinamide was 0% to 3%.
- the solutions were kept at room temperature and 5° C. for a week to assess the maintenance of the dissolved state.
- HPCD and niacinamide concentrations of HPCD and niacinamide were determined in 1% metronidazole solutions, which were clear with no precipitate. Metronidazole solubility was visually determined after a week storage. In order to evaluate the solubilization capacity of the HPCD and niacinamide combinations, the niacinamide concentration required to make 1.5% metronidazole in 5% HPCD solution was determined by keeping the solution at 5° C. for 1 week.
- HPCD When HPCD was used as a solubilizer, 5% HPCD was required to make a stable 1% metronidazole aqueous solution. When the concentration of HPCD was reduced to 4% or less, aqueous solutions containing 1% metronidazole showed a precipitation formation when kept at 5° C. for 1 week. When niacinamide was used as a solubilizer, 3% niacinamide was required to make 1% metronidazole aqueous solution. When the concentration of niacinamide was reduced to 2% or less, aqueous solutions containing 1% metronidazole showed a precipitation formation when kept at 5° C. for 1 week.
- Metronidazole was added to a 1% metronidazole solution containing 5% HPCD until the concentration reached 1.5%. The solution then showed a precipitate at room temperature. The addition of niacinamide to a concentration of 6% permitted the excess metronidazole to dissolve to reestablish a 1.5% metronidazole solution. This solution stayed clear with no precipitate for 1 week at 5° C.
- a stable 1.0% aqueous gel was prepared in accordance with the following components:
- a stable 1.5% aqueous gel was prepared in accordance with the following components:
- a stable 1.5% aqueous gel was prepared in accordance with the following components:
Abstract
Description
TABLE 1 | |||||||
Concentration of | 0.0 | 2.0 | 8.0 | 10.0 | 15.0 | ||
HPCD (% w/w) | |||||||
Solubility* of | 0.7 | 1.0 | 1.5 | 2.0 | 2.5 | ||
MTZ (% w/w) | |||||||
*Solubility of metronidazole in aqueous solutions with different HPCD concentrations estimated by solution stability following 1-day storage at room temperature followed by 1-day storage at 5° C. |
Metronidazole, USP | 1.00% | Active Ingredient | ||
Hydroxypropyl-beta- | 5.00% | Solubility Agent | ||
cyclodextrin | ||||
Methylparaben, NF | 0.15% | Antimicrobial | ||
Propylparaben, NF | 0.03% | Antimicrobial | ||
Glycerin, USP | 5.00% | Humectant | ||
Hydroxyethylcellulose, NF | 1.50% | Gelling Agent | ||
Disodium Edetate, USP | 0.05% | Chelating Agent | ||
Purified Water, USP | QS 100% | Solvent/Vehicle. | ||
Metronidazole, USP | 1.25% | Active Ingredient | ||
Hydroxypropyl-beta- | 12.00% | Solubility Agent | ||
cyclodextrin | ||||
Methylparaben, NF | 0.15% | Antimicrobial | ||
Propylparaben, NF | 0.03% | Antimicrobial | ||
Glycerin, USP | 5.00% | Humectant | ||
Hydroxyethylcellulose, NF | 1.50% | Gelling Agent | ||
Disodium Edetate, USP | 0.05% | Chelating Agent | ||
Purified Water, USP | QS 100% | Solvent/Vehicle. | ||
Metronidazole, USP | 1.0% | Active Ingredient | ||
Hydroxypropyl-beta- | 5.00% | Solubility Agent | ||
cyclodextrin | ||||
Methylparaben, NF | 0.15% | Antimicrobial | ||
Propylparaben, NF | 0.03% | Antimicrobial | ||
Hydroxyethylcellulose, NF | 1.25% | Gelling Agent | ||
Disodium Edetate, USP | 0.05% | Chelating Agent | ||
Purified Water, USP | QS 100% | Solvent/Vehicle. | ||
TABLE 2 | |||||
|
5° C. | 25° C. | 40° C. | ||
Example 2 | 3 months | 12 months | 6 months | ||
Example 3 | 3 |
3 months | 6 months | ||
Example 4 | 3 months | 12 months | 6 months | ||
TABLE 3 |
Stability of metronidazole/cyclodextrin solutions |
Cyclodextrins | MTZ % w/w | Room Temp. | 5° C. | ||
5% HPCD | 1.0 | None | None for 30 |
||
2% beta- | 1.0 | 1 day | — | ||
cyclodextrin | |||||
2.25% beta- | 1.0 | 1 day | — | ||
cyclodextrin | |||||
5% alpha- | 1.0 | None | None for 5 days | ||
cyclodextrin | |||||
5% gamma- | 1.0 | 2 days | — | ||
cyclodextrin | |||||
10% HPCD | 1.5 | None | None for 10 |
||
10% gamma- | 1.5 | 1 day | — | ||
cyclodextrin | |||||
10% alpha- | 1.5 | 1 day | — | ||
cyclodextrin | |||||
2.25% beta- | 1.5 | 1 day | — | ||
cyclodextrin | |||||
TABLE 4 | ||||
Components | Sample A | Sample B | Sample C | Sample D |
Metronidazole, USP | 1.00 | 1.00 | 0.75 | 0.75 |
HPCD | 5.00 | 5.00 | 5.00 | 0 |
Methylparaben, NF | 0.15 | 0.15 | 0.15 | 0.15 |
Propylparaben, NF | 0.03 | 0.03 | 0.03 | 0.03 |
Edetate Sodium, USP | 0.05 | 0.05 | 0.05 | 0.05 |
Hydroxyethylcellulose | 1.25 | 1.25 | 1.25 | 1.25 |
250HHX, NF | ||||
Glycerin, USP | 5.00 | 0 | 5.00 | 5.00 |
Purified Water, USP | 87.52 | 92.52 | 87.77 | 92.77 |
TABLE 5 |
Solubility of Imidazole Compounds in |
Derivatives of Betacyclodextrin |
Purified Water | 4% HPCD | 4% HECD | |
Imidazole | % w/w solubility | % w/w solubility | % w/w solubility |
Metronidazole | 0.9-1.0 | 1.1-1.2 | 1.2-1.3 |
Ketoconazole | less than 0.01 | 0.01-0.03 | 0.03-0.05 |
Itraconazole | less than 0.01 | less than 0.01 | less than 0.01 |
Metronidazole, USP | 1.0% | Active Ingredient | ||
Hydroxypropyl-beta- | 1.0% | Solubility Agent | ||
cyclodextrin | ||||
Niacinamide | 1.0% | Solubility Agent | ||
Methylparaben, NF | 0.15% | Antimicrobial | ||
Propylparaben, NF | 0.03% | Antimicrobial | ||
Hydroxyethylcellulose, NF | 1.25% | Gelling Agent | ||
Disodium Edetate, USP | 0.05% | Chelating Agent | ||
Purified Water, USP | QS 100% | Solvent/Vehicle. | ||
Metronidazole, USP | 1.5% | Active Ingredient | ||
Hydroxypropyl-beta- | 5.0% | Solubility Agent | ||
cyclodextrin | ||||
Niacinamide | 6.0% | Solubility Agent | ||
Methylparaben, NF | 0.15% | Antimicrobial | ||
Propylparaben, NF | 0.03% | Antimicrobial | ||
Hydroxyethylcellulose, NF | 1.25% | Gelling Agent | ||
Disodium Edetate, USP | 0.05% | Chelating Agent | ||
Purified Water, USP | QS 100% | Solvent/Vehicle. | ||
Metronidazole, USP | 1.5% | Active Ingredient | ||
Hydroxypropyl-beta- | 15.0% | Solubility Agent | ||
cyclodextrin | ||||
Methylparaben, NF | 0.15% | Antimicrobial | ||
Propylparaben, NF | 0.03% | Antimicrobial | ||
Hydroxyethylcellulose, NF | 1.25% | Gelling Agent | ||
Disodium Edetate, USP | 0.05% | Chelating Agent | ||
Purified Water, USP | QS 100% | Solvent/Vehicle. | ||
Claims (28)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/615,169 US6468989B1 (en) | 2000-07-13 | 2000-07-13 | Gel compositions containing metronidazole |
AT01948497T ATE506950T1 (en) | 2000-07-13 | 2001-06-19 | COMPOSITIONS CONTAINING METRONIDAZOLE |
EP01948497A EP1303541B1 (en) | 2000-07-13 | 2001-06-19 | Compositions containing metronidazole |
AU2001269937A AU2001269937A1 (en) | 2000-07-13 | 2001-06-19 | Gel compositions containing metronidazole |
CA002405072A CA2405072C (en) | 2000-07-13 | 2001-06-19 | Gel compositions containing metronidazole |
DE60144520T DE60144520D1 (en) | 2000-07-13 | 2001-06-19 | COMPOSITIONS CONTAINING METRONIDAZOLE |
ES01948497T ES2365322T3 (en) | 2000-07-13 | 2001-06-19 | COMPOSITIONS THAT INCLUDE METRTONIDAZOL. |
JP2002512249A JP4130358B2 (en) | 2000-07-13 | 2001-06-19 | Metronidazole-containing gel composition |
PCT/US2001/019644 WO2002006349A1 (en) | 2000-07-13 | 2001-06-19 | Gel compositions containing metronidazole |
ARP010103309A AR030245A1 (en) | 2000-07-13 | 2001-07-12 | GEL COMPOSITIONS CONTAINING METRONIDAZOL |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/615,169 US6468989B1 (en) | 2000-07-13 | 2000-07-13 | Gel compositions containing metronidazole |
Publications (1)
Publication Number | Publication Date |
---|---|
US6468989B1 true US6468989B1 (en) | 2002-10-22 |
Family
ID=24464287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/615,169 Expired - Lifetime US6468989B1 (en) | 2000-07-13 | 2000-07-13 | Gel compositions containing metronidazole |
Country Status (10)
Country | Link |
---|---|
US (1) | US6468989B1 (en) |
EP (1) | EP1303541B1 (en) |
JP (1) | JP4130358B2 (en) |
AR (1) | AR030245A1 (en) |
AT (1) | ATE506950T1 (en) |
AU (1) | AU2001269937A1 (en) |
CA (1) | CA2405072C (en) |
DE (1) | DE60144520D1 (en) |
ES (1) | ES2365322T3 (en) |
WO (1) | WO2002006349A1 (en) |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003057135A2 (en) * | 2001-12-24 | 2003-07-17 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
US20040265240A1 (en) * | 2003-04-28 | 2004-12-30 | Foamix Ltd. | Foamable iodine composition |
US20050090564A1 (en) * | 2003-10-28 | 2005-04-28 | Wegener Paul T. | Compositions and treatments of bacterial vaginosis |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
US20070020304A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
FR2890560A1 (en) * | 2005-09-13 | 2007-03-16 | Galderma Sa | METRONIDAZOLE DERMATOLOGICAL FOAMS AND EMULSIONS FOR THEIR PREPARATION |
FR2890559A1 (en) * | 2005-09-13 | 2007-03-16 | Galderma Sa | DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION |
WO2009082452A1 (en) | 2007-12-21 | 2009-07-02 | Dejovin Jack A | Pre-surgical treatment |
US7645803B2 (en) | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US20100105750A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
US20100130502A1 (en) * | 2003-05-27 | 2010-05-27 | Galderma Laboratories, Inc. | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders |
EP2204174A1 (en) | 2005-06-17 | 2010-07-07 | Galderma S.A. | Metronidazole solubilisation process with niacinamide and two glycols, and the resulting solution |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7893097B2 (en) | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US20110118267A1 (en) * | 2009-11-19 | 2011-05-19 | Galderma Laboratories, L.P. | Method and Kit for Treating or Preventing Psoriasis |
WO2011061252A2 (en) | 2009-11-18 | 2011-05-26 | Galderma Research & Development | Combination therapy for treating or preventing an inflammatory skin disorder |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
WO2012001064A2 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
WO2012001065A2 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US8203029B2 (en) | 1997-11-14 | 2012-06-19 | Kimberly-Clark Worldwide, Inc. | Silver-containing compositions, devices and methods for making |
EP2481412A1 (en) | 2004-05-25 | 2012-08-01 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8361553B2 (en) | 2004-07-30 | 2013-01-29 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for metal nanoparticle treated surfaces |
WO2013016086A1 (en) | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
WO2013057580A1 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method for treating capillary hemangiomas |
WO2013057579A2 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
WO2013070861A1 (en) | 2011-11-10 | 2013-05-16 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8486426B2 (en) | 2002-07-29 | 2013-07-16 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for treatment of dermal conditions |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US8513247B2 (en) | 2010-03-26 | 2013-08-20 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8679523B2 (en) | 1999-12-30 | 2014-03-25 | Kimberly-Clark Worldwide, Inc. | Oxygen-delivery closed cell foam matrix for wound treatment |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
WO2014179353A1 (en) | 2013-05-02 | 2014-11-06 | Karandikar Bhalchandra M | Antimicrobial compositions and methods of making the same |
US8900624B2 (en) | 2004-07-30 | 2014-12-02 | Kimberly-Clark Worldwide, Inc. | Antimicrobial silver compositions |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
US8946276B2 (en) | 2011-06-28 | 2015-02-03 | Watson Laboratories, Inc. | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
WO2015044788A1 (en) | 2013-09-26 | 2015-04-02 | Galderma S.A. | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US9289378B2 (en) | 2004-09-20 | 2016-03-22 | Avent, Inc. | Antimicrobial amorphous compositions |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
WO2017172761A1 (en) | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US10201517B2 (en) | 2010-10-21 | 2019-02-12 | Galderma Laboratories, L.P. | Brimonidine gel compositions and methods of use |
US10251392B2 (en) | 2004-07-30 | 2019-04-09 | Avent, Inc. | Antimicrobial devices and compositions |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10544405B2 (en) | 2013-01-16 | 2020-01-28 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
WO2022031729A1 (en) | 2020-08-04 | 2022-02-10 | Venthera, Inc. | Formulations of phosphoinositide 3-kinase inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110314133A (en) * | 2019-06-28 | 2019-10-11 | 石家庄四药有限公司 | A kind of metronidazole injection and preparation method thereof |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032645A (en) | 1975-06-19 | 1977-06-28 | G. D. Searle & Co. | Injectable metronidazole composition |
WO1985002767A1 (en) | 1983-12-21 | 1985-07-04 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
EP0335545A2 (en) | 1988-03-29 | 1989-10-04 | University Of Florida | Pharmaceutical formulations for parenteral use |
WO1990003784A1 (en) | 1988-10-05 | 1990-04-19 | Cetus Corporation | Cyclodextrin-peptide complexes |
WO1991011172A1 (en) | 1990-01-23 | 1991-08-08 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0472327A1 (en) | 1990-08-13 | 1992-02-26 | Senju Pharmaceutical Co., Ltd. | Composition for eye drops |
WO1994002518A1 (en) | 1992-07-27 | 1994-02-03 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
US5747341A (en) * | 1991-06-24 | 1998-05-05 | Pacific Biomedical Research, Inc. | Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture |
US5849776A (en) | 1994-07-06 | 1998-12-15 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Medicaments based on metronidazole or on a synergic mixture of metronidazole and clindamycin |
US5928942A (en) * | 1991-06-24 | 1999-07-27 | Pacific Biomedical Research, Inc. | Hormone-secreting cells derived from pancreatic islet maintained in long-term culture |
US6183766B1 (en) * | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950003919B1 (en) * | 1987-03-20 | 1995-04-20 | 갈데르마 에스. 에이. | Process for preparing topical metronidazole formulations |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
JPH07157440A (en) * | 1993-10-15 | 1995-06-20 | Takeda Chem Ind Ltd | Composition for medicine |
JP2001513563A (en) * | 1997-08-27 | 2001-09-04 | ヘキサル アーゲー | Pharmaceutical composition of meloxicam with improved solubility and bioavailability |
US5989523A (en) * | 1998-03-20 | 1999-11-23 | Fitzjarrell; Edwin A. | Topical spray for treating acne containing niacinamide and NaPCA |
CN1317967A (en) * | 1998-09-17 | 2001-10-17 | 伊莱利利公司 | Protein formulations |
EP1383445A4 (en) * | 2001-03-20 | 2005-04-13 | Cydex Inc | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
US6881726B2 (en) * | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
-
2000
- 2000-07-13 US US09/615,169 patent/US6468989B1/en not_active Expired - Lifetime
-
2001
- 2001-06-19 AT AT01948497T patent/ATE506950T1/en not_active IP Right Cessation
- 2001-06-19 AU AU2001269937A patent/AU2001269937A1/en not_active Abandoned
- 2001-06-19 EP EP01948497A patent/EP1303541B1/en not_active Expired - Lifetime
- 2001-06-19 CA CA002405072A patent/CA2405072C/en not_active Expired - Fee Related
- 2001-06-19 WO PCT/US2001/019644 patent/WO2002006349A1/en active Application Filing
- 2001-06-19 ES ES01948497T patent/ES2365322T3/en not_active Expired - Lifetime
- 2001-06-19 JP JP2002512249A patent/JP4130358B2/en not_active Expired - Lifetime
- 2001-06-19 DE DE60144520T patent/DE60144520D1/en not_active Expired - Lifetime
- 2001-07-12 AR ARP010103309A patent/AR030245A1/en active IP Right Grant
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032645A (en) | 1975-06-19 | 1977-06-28 | G. D. Searle & Co. | Injectable metronidazole composition |
WO1985002767A1 (en) | 1983-12-21 | 1985-07-04 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
EP0149197A2 (en) | 1983-12-21 | 1985-07-24 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are sparingly soluble in water or instable and methods for their preparation |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4837378A (en) * | 1986-01-15 | 1989-06-06 | Curatek Pharmaceuticals, Inc. | Topical metronidazole formulations and therapeutic uses thereof |
US5536743A (en) | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
EP0335545A2 (en) | 1988-03-29 | 1989-10-04 | University Of Florida | Pharmaceutical formulations for parenteral use |
WO1990003784A1 (en) | 1988-10-05 | 1990-04-19 | Cetus Corporation | Cyclodextrin-peptide complexes |
WO1991011172A1 (en) | 1990-01-23 | 1991-08-08 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
EP0472327A1 (en) | 1990-08-13 | 1992-02-26 | Senju Pharmaceutical Co., Ltd. | Composition for eye drops |
US5747341A (en) * | 1991-06-24 | 1998-05-05 | Pacific Biomedical Research, Inc. | Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture |
US5928942A (en) * | 1991-06-24 | 1999-07-27 | Pacific Biomedical Research, Inc. | Hormone-secreting cells derived from pancreatic islet maintained in long-term culture |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
WO1994002518A1 (en) | 1992-07-27 | 1994-02-03 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US5849776A (en) | 1994-07-06 | 1998-12-15 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Medicaments based on metronidazole or on a synergic mixture of metronidazole and clindamycin |
US6183766B1 (en) * | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
Non-Patent Citations (25)
Title |
---|
Andersen, FM, and Bundgaard, H, Inclusion complexation of metronidazole benzoate with beta-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions, International Journal of Pharmaceutics, vol. 19:189-197 (1984). |
Andersen, FM, and Bundgaard, H, Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions, International Journal of Pharmaceutics, vol. 19:189-197 (1984). |
Chien, Yw, Solubilization of Metronidazole by Water-miscible Multi-cosolvents and Water-soluble Vitamins, Journal of Parenteral Science and Technology, vol. 38(1):32-36 (1984). |
European Phamacopoeia, pp. 980-981 (1995). |
Giordano, F., et al., Preparation and Characterization of Metronidazole Benzoate-Gammacyclodextrin Inclusion Compound, Boll. Chim. Farmaceutico, vol. 131(4):150-156 (1992). |
Hadi, Ia al, Formulation factors and physical properties of metronidazole benzoate tablets containing mixtures of beta-cyclodextrins and its derivatives, Congr. Int. Tech. Pharm., 6th, 5:401-407 (1992). |
Hadi, Ia al, Formulation factors and physical properties of metronidazole benzoate tablets containing mixtures of β-cyclodextrins and its derivatives, Congr. Int. Tech. Pharm., 6th, 5:401-407 (1992). |
Hassan et al., Improvement of the in vitro dissolution characteristics of famotidine by inclusion in betacyclodextrin, International Journal of Pharmaceutics, 58:19-24 (1990. |
Hassan et al., Improvement of the in vitro dissolution characteristics of famotidine by inclusion in βcyclodextrin, International Journal of Pharmaceutics, 58:19-24 (1990. |
Hirayama et al., in Cyclodextrins and their Industrial Uses, ed. D. Duchene, Editions de Sante, Paris, 1987, pp. 133-172. |
Kata, M., and Antal, A., Production and Investigation of products containing metronidazole and beta-cyclodextrin, Acta Pharmaceutica Hungarica, 54:116-122 (1984). |
Kata, M., and Antal, A., Production and Investigation of products containing metronidazole and β-cyclodextrin, Acta Pharmaceutica Hungarica, 54:116-122 (1984). |
Kata, M., and Kedvessy, G., Increasing the solubility characteristics of Pharmaca with cyclodextrins, Pharm. Ind., vol. 49:98-100 (1987). |
Lofftson et al., 2-Hydroxypropyl-beta-cyclodextrin: Properties and Usage in Pharmaceautical Formulations, Phar. Ztg. Wiss., vol. 4/13:5-10 (1991). |
Lofftson et al., 2-Hydroxypropyl-β-cyclodextrin: Properties and Usage in Pharmaceautical Formulations, Phar. Ztg. Wiss., vol. 4/13:5-10 (1991). |
Loftsson, T., and Bodor, N., Effects of 2-hydroxypropyl-beta-cyclodextrin on the aqueous solubility of drugs and transderman delivery of 17 betaestradiol, Acta. Pharm. Nord., 1(4):185-193 (1989). |
Loftsson, T., and Bodor, N., Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of drugs and transderman delivery of 17 βestradiol, Acta. Pharm. Nord., 1(4):185-193 (1989). |
Loftsson, T., et al., The effects of cyclodextrin on transdermal delivery of drugs, European J. Pharm. Biopharm., 37(1):30-33 (1991). |
Pagington, J.S., beta-Cyclodextrin: the success of molecular inclusion, Chemistry in Britain, pp. 455-458 (May 1987). |
Pagington, J.S., β-Cyclodextrin: the success of molecular inclusion, Chemistry in Britain, pp. 455-458 (May 1987). |
Physicians Desk Reference, 53 Edition, pp. 912-913 (1999). |
Skiba, M., et al., Development of a new colloidal drug carrier from chemically-modified cyclodextrins: nanospheres and infulence of physicochemical and technological factors on particle size, International Journal of Pharmaceutics, vol. 129:113-121 (1996). |
Szejtli, J., Cyclodextrins in Drug Formulations: Part 1, Pharmaceutical Technology International, vol. 3(2):15-22 (1991). |
Szejtli, J., Cyclodextrins in Drug Formulations: Part 2 Pharmaceutical Technology International, vol. 3(3):16-24 (1991). |
Uekama, K, and Otagiri, M, Cyclodextrins in Drug Carrier Systems, CRC Critical Review in Therapeutic Drug Carrier Systems, vol. 3(1):1-40 (1987). |
Cited By (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8203029B2 (en) | 1997-11-14 | 2012-06-19 | Kimberly-Clark Worldwide, Inc. | Silver-containing compositions, devices and methods for making |
US9687503B2 (en) | 1999-12-30 | 2017-06-27 | Avent, Inc. | Devices for delivering oxygen to the wounds |
US8679523B2 (en) | 1999-12-30 | 2014-03-25 | Kimberly-Clark Worldwide, Inc. | Oxygen-delivery closed cell foam matrix for wound treatment |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
US7348317B2 (en) | 2001-12-24 | 2008-03-25 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
WO2003057135A3 (en) * | 2001-12-24 | 2003-12-18 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
US6881726B2 (en) * | 2001-12-24 | 2005-04-19 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
US20050124578A1 (en) * | 2001-12-24 | 2005-06-09 | Yunik Chang | Aqueous compositions containing metronidazole |
WO2003057135A2 (en) * | 2001-12-24 | 2003-07-17 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
US20100048659A1 (en) * | 2001-12-24 | 2010-02-25 | Yunik Chang | Aqueous compositions containing metronidazole |
US20080154030A1 (en) * | 2001-12-24 | 2008-06-26 | Yunik Chang | Method for increasing the solubility of betacyclodextrin |
US8486426B2 (en) | 2002-07-29 | 2013-07-16 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for treatment of dermal conditions |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US20070020304A1 (en) * | 2002-10-25 | 2007-01-25 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
US20040265240A1 (en) * | 2003-04-28 | 2004-12-30 | Foamix Ltd. | Foamable iodine composition |
EP2815748A1 (en) | 2003-05-27 | 2014-12-24 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing rosacea |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US8426410B2 (en) | 2003-05-27 | 2013-04-23 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US7838563B2 (en) | 2003-05-27 | 2010-11-23 | Galderma Laboratories Inc. | Compounds, formulations, and methods for ameliorating telangiectasias |
US20100227867A1 (en) * | 2003-05-27 | 2010-09-09 | Galderma Laboratories Inc. | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders |
EP2388007A1 (en) | 2003-05-27 | 2011-11-23 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing rosacea |
US20100130502A1 (en) * | 2003-05-27 | 2010-05-27 | Galderma Laboratories, Inc. | Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders |
US8586586B2 (en) | 2003-05-27 | 2013-11-19 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US8993571B2 (en) | 2003-05-27 | 2015-03-31 | Galderma Laboratories, L.P. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20050090564A1 (en) * | 2003-10-28 | 2005-04-28 | Wegener Paul T. | Compositions and treatments of bacterial vaginosis |
EP2481412A1 (en) | 2004-05-25 | 2012-08-01 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US10251392B2 (en) | 2004-07-30 | 2019-04-09 | Avent, Inc. | Antimicrobial devices and compositions |
US8361553B2 (en) | 2004-07-30 | 2013-01-29 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for metal nanoparticle treated surfaces |
US8900624B2 (en) | 2004-07-30 | 2014-12-02 | Kimberly-Clark Worldwide, Inc. | Antimicrobial silver compositions |
US9888691B2 (en) | 2004-07-30 | 2018-02-13 | Avent, Inc. | Antimicrobial silver compositions |
US9289378B2 (en) | 2004-09-20 | 2016-03-22 | Avent, Inc. | Antimicrobial amorphous compositions |
WO2006047590A3 (en) * | 2004-10-26 | 2006-07-06 | Mitsui Norin Kk | Compositions and treatments of bacterial vaginosis |
WO2006047590A2 (en) * | 2004-10-26 | 2006-05-04 | Mitsui Norin Co., Ltd. | Compositions and treatments of bacterial vaginosis |
US20060093675A1 (en) * | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
US20070231358A1 (en) * | 2004-10-29 | 2007-10-04 | Tolmar, Inc. | Intravaginal treatment of vaginal infections with metronidazole compositions |
US20090030060A1 (en) * | 2004-10-29 | 2009-01-29 | Tolmar, Inc. | Intravaginal treatment of vaginal infections with metronidazole compositions |
US7645803B2 (en) | 2005-05-09 | 2010-01-12 | Foamix Ltd. | Saccharide foamable compositions |
EP2204174A1 (en) | 2005-06-17 | 2010-07-07 | Galderma S.A. | Metronidazole solubilisation process with niacinamide and two glycols, and the resulting solution |
WO2007031621A2 (en) * | 2005-09-13 | 2007-03-22 | Galderma S.A | Metronidazole-based dermatological foam and emulsions for the production thereof |
US20110237638A1 (en) * | 2005-09-13 | 2011-09-29 | Galderma S.A. | Metronidazole-based dermatological foam and emulsions for the preparation thereof |
FR2890560A1 (en) * | 2005-09-13 | 2007-03-16 | Galderma Sa | METRONIDAZOLE DERMATOLOGICAL FOAMS AND EMULSIONS FOR THEIR PREPARATION |
WO2007031620A3 (en) * | 2005-09-13 | 2007-05-03 | Galderma Sa | Metronidazole-based dermatological foam and emulsions for the production thereof |
US20110237637A1 (en) * | 2005-09-13 | 2011-09-29 | Galderma S.A. | Metronidazole-based dermatological foam and emulsions for the production thereof |
WO2007031621A3 (en) * | 2005-09-13 | 2007-05-03 | Galderma Sa | Metronidazole-based dermatological foam and emulsions for the production thereof |
US20090053146A1 (en) * | 2005-09-13 | 2009-02-26 | Galderma S.A. | Metronidazole-based dermatological foams and emulsions for the preparation thereof |
US20090041678A1 (en) * | 2005-09-13 | 2009-02-12 | Galderma S.A., Cham, Switzerland. | Metronidazole-based dermatological foams and emulsions for the preparation thereof |
WO2007031620A2 (en) * | 2005-09-13 | 2007-03-22 | Galderma S.A. | Metronidazole-based dermatological foam and emulsions for the production thereof |
FR2890559A1 (en) * | 2005-09-13 | 2007-03-16 | Galderma Sa | DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION |
US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
WO2009082452A1 (en) | 2007-12-21 | 2009-07-02 | Dejovin Jack A | Pre-surgical treatment |
US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US8658678B2 (en) | 2008-02-02 | 2014-02-25 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US20110082179A1 (en) * | 2008-02-02 | 2011-04-07 | Meidong Yang | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US7893097B2 (en) | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US8877792B2 (en) | 2008-02-02 | 2014-11-04 | Dow Pharmaceutical Sciences, Inc. | Compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US20100105750A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
EP2329849A1 (en) | 2009-11-18 | 2011-06-08 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
WO2011061252A2 (en) | 2009-11-18 | 2011-05-26 | Galderma Research & Development | Combination therapy for treating or preventing an inflammatory skin disorder |
US9186358B2 (en) | 2009-11-18 | 2015-11-17 | Galderma Laboratories, L.P. | Combination therapy for treating or preventing an inflammatory skin disorder |
WO2011075267A1 (en) | 2009-11-19 | 2011-06-23 | Galderma Laboratories Lp | Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US9072739B2 (en) | 2009-11-19 | 2015-07-07 | Galderma Laboratories, L.P. | Method for treating psoriasis |
US20110118267A1 (en) * | 2009-11-19 | 2011-05-19 | Galderma Laboratories, L.P. | Method and Kit for Treating or Preventing Psoriasis |
US9861632B2 (en) | 2010-03-26 | 2018-01-09 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
US8513247B2 (en) | 2010-03-26 | 2013-08-20 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
US8916562B2 (en) | 2010-03-26 | 2014-12-23 | Galderma Research & Development Snc | Methods and compositions for safe and effective treatment of telangiectasia |
US8513249B2 (en) | 2010-03-26 | 2013-08-20 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
US9861631B2 (en) | 2010-03-26 | 2018-01-09 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
WO2012001065A2 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
WO2012001064A2 (en) | 2010-06-30 | 2012-01-05 | Galderma Research & Development | Method for preventing or treating skin tumor |
US8163725B1 (en) | 2010-10-21 | 2012-04-24 | Galderma R&D SNC | Gel compositions and methods of use |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
US10201517B2 (en) | 2010-10-21 | 2019-02-12 | Galderma Laboratories, L.P. | Brimonidine gel compositions and methods of use |
US10238634B2 (en) | 2011-06-28 | 2019-03-26 | Chemo Research, S.L. | Aqueous-based metronidazole gel formulations |
US8946276B2 (en) | 2011-06-28 | 2015-02-03 | Watson Laboratories, Inc. | High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis |
US10596155B2 (en) | 2011-06-28 | 2020-03-24 | Chemo Research, S.L. | Aqueous-based metronidazole gel formulations |
US9198858B2 (en) | 2011-06-28 | 2015-12-01 | Watson Pharmaceuticals, Inc. | Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations |
WO2013016086A1 (en) | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
WO2013016072A1 (en) | 2011-07-22 | 2013-01-31 | Allergan, Inc. | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
WO2013057579A2 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
WO2013057580A1 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method for treating capillary hemangiomas |
EP3763370A1 (en) | 2011-11-10 | 2021-01-13 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline |
EP3184110A1 (en) | 2011-11-10 | 2017-06-28 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline |
US10201535B2 (en) | 2011-11-10 | 2019-02-12 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US9308201B2 (en) | 2011-11-10 | 2016-04-12 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
WO2013070861A1 (en) | 2011-11-10 | 2013-05-16 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US11312945B2 (en) | 2013-01-16 | 2022-04-26 | Emory University | CAS9-nucleic acid complexes and uses related thereto |
US10544405B2 (en) | 2013-01-16 | 2020-01-28 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US9757387B2 (en) | 2013-05-02 | 2017-09-12 | Medical Technology Research Inc | Antimicrobial compositions and methods of making the same |
US10350219B2 (en) | 2013-05-02 | 2019-07-16 | Medical Technology Research Inc | Antimicrobial compositions and methods of making the same |
WO2014179353A1 (en) | 2013-05-02 | 2014-11-06 | Karandikar Bhalchandra M | Antimicrobial compositions and methods of making the same |
WO2015044788A1 (en) | 2013-09-26 | 2015-04-02 | Galderma S.A. | Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US11117860B2 (en) | 2016-03-28 | 2021-09-14 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
WO2017172761A1 (en) | 2016-03-28 | 2017-10-05 | Allergan, Inc. | Phenyl urea derivatives as n-formyl peptide receptor modulators |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
WO2022031729A1 (en) | 2020-08-04 | 2022-02-10 | Venthera, Inc. | Formulations of phosphoinositide 3-kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA2405072C (en) | 2007-08-28 |
ES2365322T3 (en) | 2011-09-29 |
EP1303541B1 (en) | 2011-04-27 |
JP4130358B2 (en) | 2008-08-06 |
AR030245A1 (en) | 2003-08-13 |
ATE506950T1 (en) | 2011-05-15 |
EP1303541A4 (en) | 2007-01-31 |
EP1303541A1 (en) | 2003-04-23 |
DE60144520D1 (en) | 2011-06-09 |
AU2001269937A1 (en) | 2002-01-30 |
CA2405072A1 (en) | 2002-01-24 |
JP2004515463A (en) | 2004-05-27 |
WO2002006349A1 (en) | 2002-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6468989B1 (en) | Gel compositions containing metronidazole | |
US7348317B2 (en) | Aqueous compositions containing metronidazole | |
EP0814844B1 (en) | Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same | |
WO2017127835A2 (en) | Aqueous formulations and methods of preparation and use thereof | |
KR20090084925A (en) | Liquid preparation comprising a complex of pimobendan and cyclodextrin | |
US20100105750A1 (en) | Stable metronidazole gel formulations | |
CN113181110A (en) | Liquid aqueous pharmaceutical composition containing preserved etherified cyclodextrin derivatives | |
Loftsson | Formulation of drug-cyclodextrin complexes | |
Ramos-Martínez et al. | Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations? | |
BR112015016331B1 (en) | STABILIZED PHARMACEUTICAL FORMULATION AND STABILIZATION METHOD OF A COMPOSITION UNDERSTANDING VORICONAZOLE | |
WO2004082589A2 (en) | Nasally administrable, bioavailable pharmaceutical composition of loratadine | |
JP6742920B2 (en) | Hydroalcoholic system for treating nails | |
US20080287513A1 (en) | Topical compositions containing metronidazole | |
AU2015255164B2 (en) | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DOW PHARMACEUTICAL SCIENCES, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANG, YUNIK;DOW, GORDON;ANGEL, ARTURO;REEL/FRAME:011262/0260 Effective date: 20000721 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL Free format text: SECURITY AGREEMENT;ASSIGNORS:ATON PHARMA, INC.;VALEANT PHARMACEUTICALS NORTH AMERICA;VALEANT PHARMACEUTICALS INTERNATIONAL;AND OTHERS;REEL/FRAME:025084/0169 Effective date: 20100927 |
|
AS | Assignment |
Owner name: VALEANT PHARMACEUTICALS INTERNATIONAL, CALIFORNIA Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0048 Effective date: 20110308 Owner name: CORIA LABORATORIES, LTD., TEXAS Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0048 Effective date: 20110308 Owner name: DOW PHARMACEUTICAL SCIENCES, INC., CALIFORNIA Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0048 Effective date: 20110308 Owner name: ATON PHARMA, INC., NEW JERSEY Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0048 Effective date: 20110308 Owner name: VALEANT PHARMACEUTICALS NORTH AMERICA, CALIFORNIA Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0048 Effective date: 20110308 |
|
AS | Assignment |
Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL Free format text: SECURITY AGREEMENT;ASSIGNORS:VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION;ATON PHARMA, INC., A DELAWARE CORPORATION;CORIA LABORATORIES, LTD., A DELAWARE CORPORATION;AND OTHERS;REEL/FRAME:026606/0061 Effective date: 20110629 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: BARCLAYS BANK PLC, AS SUCCESSOR AGENT, NEW YORK Free format text: NOTICE OF SUCCESSION OF AGENCY;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS, LLC;REEL/FRAME:034749/0689 Effective date: 20150108 |
|
AS | Assignment |
Owner name: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:ATON PHARMA, INC.;BAUSCH & LOMB INCORPORATED;BAUSCH & LOMB PHARMA HOLDINGS CORP.;AND OTHERS;REEL/FRAME:045444/0634 Effective date: 20180213 Owner name: BARCLAYS BANK PLC, AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:ATON PHARMA, INC.;BAUSCH & LOMB INCORPORATED;BAUSCH & LOMB PHARMA HOLDINGS CORP.;AND OTHERS;REEL/FRAME:045444/0299 Effective date: 20180213 Owner name: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT, Free format text: SECURITY INTEREST;ASSIGNORS:ATON PHARMA, INC.;BAUSCH & LOMB INCORPORATED;BAUSCH & LOMB PHARMA HOLDINGS CORP.;AND OTHERS;REEL/FRAME:045444/0634 Effective date: 20180213 |
|
AS | Assignment |
Owner name: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL A Free format text: SECURITY INTEREST;ASSIGNORS:BAUSCH HEALTH AMERICAS, INC.;BAUSCH & LOMB INCORPORATED;BAUSCH HEALTH US, LLC;AND OTHERS;REEL/FRAME:048556/0758 Effective date: 20190308 Owner name: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:BAUSCH HEALTH AMERICAS, INC.;BAUSCH & LOMB INCORPORATED;BAUSCH HEALTH US, LLC;AND OTHERS;REEL/FRAME:048556/0758 Effective date: 20190308 |
|
AS | Assignment |
Owner name: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT, Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:BAUSCH HEALTH IRELAND LIMITED;BAUSCH HEALTH COMPANIES INC.;BAUSCH HEALTH, CANADA INC.;AND OTHERS;REEL/FRAME:049672/0652 Effective date: 20190701 Owner name: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT, NEW YORK Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:BAUSCH HEALTH IRELAND LIMITED;BAUSCH HEALTH COMPANIES INC.;BAUSCH HEALTH, CANADA INC.;AND OTHERS;REEL/FRAME:049672/0652 Effective date: 20190701 |